Clinical Trial Update: A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 clinical study of TQB2029 for injection in subjects with multiple myeloma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• TQB2029

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Conditions: Multiple Myeloma | Phase 1 | Status: RECRUITING